Literature DB >> 12876144

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Gareth Pryce1, Zubair Ahmed, Deborah J R Hankey, Samuel J Jackson, J Ludovic Croxford, Jennifer M Pocock, Catherine Ledent, Axel Petzold, Alan J Thompson, Gavin Giovannoni, M Louise Cuzner, David Baker.   

Abstract

Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalo myelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice deficient in the cannabinoid receptor CB1 tolerate inflammatory and excitotoxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB1 agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876144     DOI: 10.1093/brain/awg224

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  83 in total

Review 1.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

2.  Multiple sclerosis may disrupt endocannabinoid brain protection mechanism.

Authors:  Esther Shohami; Raphael Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

3.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 4.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

5.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

Review 6.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

7.  Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats.

Authors:  Yannick Marchalant; Francesca Cerbai; Holly M Brothers; Gary L Wenk
Journal:  Neurobiol Aging       Date:  2007-06-11       Impact factor: 4.673

Review 8.  Inflammation in neurodegenerative diseases--an update.

Authors:  Sandra Amor; Laura A N Peferoen; Daphne Y S Vogel; Marjolein Breur; Paul van der Valk; David Baker; Johannes M van Noort
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

9.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

10.  Cannabinoid rescue of striatal progenitor cells in chronic Borna disease viral encephalitis in rats.

Authors:  Marylou V Solbrig; Neal Hermanowicz
Journal:  J Neurovirol       Date:  2008-05       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.